Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Activity of Mesothelin-specific Chimeric Antigen Receptor T cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.

Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, Gladney WL, Levine BL, Melenhorst JJ, Plesa G, June CH.

Gastroenterology. 2018 Mar 19. pii: S0016-5085(18)30323-8. doi: 10.1053/j.gastro.2018.03.029. [Epub ahead of print]

PMID:
29567081
2.

CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients.

Karakasheva TA, Dominguez GA, Hashimoto A, Lin EW, Chiu C, Sasser K, Lee JW, Beatty GL, Gabrilovich DI, Rustgi AK.

JCI Insight. 2018 Mar 22;3(6). pii: 97022. doi: 10.1172/jci.insight.97022. [Epub ahead of print]

3.

Lysosomes support the degradation, signaling, and mitochondrial metabolism necessary for human epidermal differentiation.

Monteleon CL, Agnihotri T, Dahal A, Liu M, Rebecca VW, Beatty GL, Amavaradi RK, Ridky TW.

J Invest Dermatol. 2018 Mar 8. pii: S0022-202X(18)30216-1. doi: 10.1016/j.jid.2018.02.035. [Epub ahead of print]

PMID:
29526763
4.

Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance.

Long KB, Collier AI, Beatty GL.

Mol Immunol. 2017 Dec 19. pii: S0161-5890(17)30596-5. doi: 10.1016/j.molimm.2017.12.003. [Epub ahead of print]

PMID:
29273393
5.

CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer.

Bengsch F, Knoblock DM, Liu A, McAllister F, Beatty GL.

Cancer Immunol Immunother. 2017 Dec;66(12):1609-1617. doi: 10.1007/s00262-017-2053-4. Epub 2017 Aug 30.

PMID:
28856392
6.

IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.

Long KB, Tooker G, Tooker E, Luque SL, Lee JW, Pan X, Beatty GL.

Mol Cancer Ther. 2017 Sep;16(9):1898-1908. doi: 10.1158/1535-7163.MCT-16-0899. Epub 2017 Jun 13.

PMID:
28611107
7.

Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance.

Beatty GL, Eghbali S, Kim R.

Am Soc Clin Oncol Educ Book. 2017;37:267-278. doi: 10.14694/EDBK_175232.

8.

Functio Laesa: Cancer Inflammation and Therapeutic Resistance.

Liu M, Kalbasi A, Beatty GL.

J Oncol Pract. 2017 Mar;13(3):173-180. doi: 10.1200/JOP.2016.020347. Review.

9.

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle PA, Newton RC, Schaub R, Maleski J, Leopold L, Gajewski TF.

Clin Cancer Res. 2017 Jul 1;23(13):3269-3276. doi: 10.1158/1078-0432.CCR-16-2272. Epub 2017 Jan 4.

PMID:
28053021
10.

Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.

Beatty GL, Li Y, Long KB.

Expert Rev Anticancer Ther. 2017 Feb;17(2):175-186. doi: 10.1080/14737140.2017.1270208. Epub 2016 Dec 14. Review.

11.

Expanding Tumor Lymphocytic Infiltration as a Prognostic Tool to Patients with NSCLC Who Are Treated with Radiotherapy?

Kalbasi A, Beatty GL, Berman AT.

J Thorac Oncol. 2016 Nov;11(11):e141-e142. doi: 10.1016/j.jtho.2016.07.029. No abstract available.

12.

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.

Zhang Y, Velez-Delgado A, Mathew E, Li D, Mendez FM, Flannagan K, Rhim AD, Simeone DM, Beatty GL, Pasca di Magliano M.

Gut. 2017 Jan;66(1):124-136. doi: 10.1136/gutjnl-2016-312078. Epub 2016 Jul 8.

13.

Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.

Beatty GL, O'Hara M.

Pharmacol Ther. 2016 Oct;166:30-9. doi: 10.1016/j.pharmthera.2016.06.010. Epub 2016 Jun 29. Review.

14.

Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma.

Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, Ben-Josef E, Beatty GL.

Clin Cancer Res. 2017 Jan 1;23(1):137-148. doi: 10.1158/1078-0432.CCR-16-0870. Epub 2016 Jun 28.

15.

Overcoming Therapeutic Resistance by Targeting Cancer Inflammation.

Beatty GL.

Am Soc Clin Oncol Educ Book. 2016;35:e168-73. doi: 10.14694/EDBK_158948. Review.

16.
17.

IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma.

Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL.

Cancer Discov. 2016 Apr;6(4):400-413. doi: 10.1158/2159-8290.CD-15-1032. Epub 2016 Feb 19.

18.
19.

Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.

Beatty GL, Winograd R, Evans RA, Long KB, Luque SL, Lee JW, Clendenin C, Gladney WL, Knoblock DM, Guirnalda PD, Vonderheide RH.

Gastroenterology. 2015 Jul;149(1):201-10. doi: 10.1053/j.gastro.2015.04.010. Epub 2015 Apr 14.

20.

Immune escape mechanisms as a guide for cancer immunotherapy.

Beatty GL, Gladney WL.

Clin Cancer Res. 2015 Feb 15;21(4):687-92. doi: 10.1158/1078-0432.CCR-14-1860. Epub 2014 Dec 12. Review.

21.
22.

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH.

Cancer Immunol Res. 2013 Jul;1(1):26-31. doi: 10.1158/2326-6066.CIR-13-0006. Epub 2013 Apr 7.

23.

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH.

Cancer Immunol Res. 2014 Feb;2(2):112-20. doi: 10.1158/2326-6066.CIR-13-0170. Erratum in: Cancer Immunol Res. 2015 Feb;3(2):217.

24.

Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma.

Beatty GL.

Oncoimmunology. 2013 Dec 1;2(12):e26837. Epub 2013 Oct 22.

25.

Harnessing the antitumor potential of macrophages for cancer immunotherapy.

Long KB, Beatty GL.

Oncoimmunology. 2013 Dec 1;2(12):e26860. Epub 2013 Nov 4. Review.

26.

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH.

Cancer Immunol Res. 2013 Jul;1:26-31.

27.

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.

Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer PJ.

Clin Cancer Res. 2013 Nov 15;19(22):6286-95. doi: 10.1158/1078-0432.CCR-13-1320. Epub 2013 Aug 27.

28.

CD40 immunotherapy for pancreatic cancer.

Vonderheide RH, Bajor DL, Winograd R, Evans RA, Bayne LJ, Beatty GL.

Cancer Immunol Immunother. 2013 May;62(5):949-54. doi: 10.1007/s00262-013-1427-5. Epub 2013 Apr 16. Review.

29.

Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH.

Cancer Cell. 2012 Jun 12;21(6):822-35. doi: 10.1016/j.ccr.2012.04.025.

30.

EMT and dissemination precede pancreatic tumor formation.

Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ.

Cell. 2012 Jan 20;148(1-2):349-61. doi: 10.1016/j.cell.2011.11.025.

31.

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.

Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH.

Science. 2011 Mar 25;331(6024):1612-6. doi: 10.1126/science.1198443.

32.

Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation.

Beatty GL, Smith JS, Reshef R, Patel KP, Colligon TA, Vance BA, Frey NV, Johnson FB, Porter DL, Vonderheide RH.

Clin Cancer Res. 2009 Aug 1;15(15):4944-53. doi: 10.1158/1078-0432.CCR-08-3332. Epub 2009 Jul 14.

33.

Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers.

Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, Kaplan DE, Chang KM, Domchek SM, Kanetsky PA, Fecher LA, Flaherty KT, Schuchter LM, Vonderheide RH.

Clin Cancer Res. 2009 Jul 1;15(13):4277-87. doi: 10.1158/1078-0432.CCR-09-0537. Epub 2009 Jun 23.

34.

Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer.

Clark CE, Beatty GL, Vonderheide RH.

Cancer Lett. 2009 Jun 28;279(1):1-7. doi: 10.1016/j.canlet.2008.09.037. Epub 2008 Nov 14. Review.

PMID:
19013709
35.

Telomerase as a universal tumor antigen for cancer vaccines.

Beatty GL, Vonderheide RH.

Expert Rev Vaccines. 2008 Sep;7(7):881-7. doi: 10.1586/14760584.7.7.881. Review.

PMID:
18767939
36.

Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.

Beatty GL, Giantonio BJ.

Expert Rev Anticancer Ther. 2008 May;8(5):683-8. doi: 10.1586/14737140.8.5.683. Review.

PMID:
18471041
37.

Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance.

Domchek SM, Recio A, Mick R, Clark CE, Carpenter EL, Fox KR, DeMichele A, Schuchter LM, Leibowitz MS, Wexler MH, Vance BA, Beatty GL, Veloso E, Feldman MD, Vonderheide RH.

Cancer Res. 2007 Nov 1;67(21):10546-55.

38.

Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.

Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Kolstad A, Fox R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE, Bishop MR.

Biol Blood Marrow Transplant. 2006 Nov;12(11):1150-60.

39.

Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors.

Dominiecki ME, Beatty GL, Pan ZK, Neeson P, Paterson Y.

Cancer Immunol Immunother. 2005 May;54(5):477-88. Epub 2004 Oct 6.

PMID:
15750832
40.

Regulation of tumor growth by IFN-gamma in cancer immunotherapy.

Beatty GL, Paterson Y.

Immunol Res. 2001;24(2):201-10. Review.

PMID:
11594457
42.

Unusual granulomas of the cecum.

BEATTY GL, MINCKS JR, PULASKI EJ.

Surgery. 1957 Feb;41(2):287-91. No abstract available.

PMID:
13401360
43.

Acute appendicitis, tetracycline prophylaxis and wound infection.

BEATTY GL, MINCKS JR, PULASKI EJ.

Antibiotic Med Clin Ther (New York). 1956 Nov;3(6):392-8. No abstract available.

PMID:
13363380
44.

Lymphoid polyps of the rectum; report of three cases in siblings.

BEATTY GL, KEELING WM.

AMA Arch Surg. 1956 Nov;73(5):753-6. No abstract available.

PMID:
13361732
45.

Experiences with a trauma ward; a report on the first six months of operation.

BEATTY GL.

U S Armed Forces Med J. 1956 Aug;7(8):1093-100. No abstract available.

PMID:
13352546
46.

Congenital atresia of the esophagus with tracheoesophageal fistula.

THOMAS PA, MASON RE, BEATTY GL.

U S Armed Forces Med J. 1956 Jul;7(7):987-96. No abstract available.

PMID:
13325101
47.

Tetracycline therapy of surgical infections.

PULASKI EJ, BEATTY GL.

Surg Gynecol Obstet. 1956 Jan;102(1):9-17. No abstract available.

PMID:
13299011

Supplemental Content

Loading ...
Support Center